We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Rejects Correvio’s Atrial Fibrillation Treatment over Safety Data
FDA Rejects Correvio’s Atrial Fibrillation Treatment over Safety Data
Correvio Pharma drew a complete response letter from the FDA for its atrial fibrillation treatment Brinavess (vernakalant) because of inadequate safety data.